AKBA (STOCKS)
Akebia Therapeutics, Inc.
$0.872100
-0.021100 (-2.36%)
Prev close: $0.893200
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- John P. Butler
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $242.36M
- Employees
- 181
- P/E (TTM)
- -8.04
- P/B (TTM)
- 9.70
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.03 | $-0.04 | +0.0149 | +33.18% |
|
Mar 2026 (Q1)
|
$-0.03 | $-0.03 | -0.0014 | -4.90% |
|
Dec 2025 (Q4)
|
$-0.05 | $-0.03 | -0.0245 | -96.08% |
|
Sep 2025 (Q3)
|
$0.00 | $-0.02 | +0.0179 | +100.00% |
Financial Statements
| Revenues | $219.06M |
| Benefits Costs and Expenses | $246.91M |
| Cost Of Revenue | $44.63M |
| Costs And Expenses | $246.91M |
| Gross Profit | $174.43M |
| Operating Expenses | $189.55M |
| Selling, General, and Administrative Expenses | $113.79M |
| Research and Development | $70.46M |
| Other Operating Expenses | $5.31M |
| Operating Income/Loss | -$15.13M |
| Income/Loss From Continuing Operations After Tax | -$29.67M |
| Income/Loss From Continuing Operations Before Tax | -$27.85M |
| Income Tax Expense/Benefit | $1.82M |
| Net Income/Loss | -$29.67M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$29.67M |
| Net Income/Loss Available To Common Stockholders, Basic | -$29.67M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.12 |
| Diluted Earnings Per Share | -$0.12 |
| Basic Average Shares | 535,885,524 |
| Diluted Average Shares | 537,181,373 |
| Assets | $349.66M |
| Current Assets | $229.55M |
| Inventory | $13.02M |
| Other Current Assets | $216.54M |
| Noncurrent Assets | $120.11M |
| Fixed Assets | $1.51M |
| Other Non-current Assets | $118.59M |
| Liabilities | $324.64M |
| Current Liabilities | $160.87M |
| Accounts Payable | $9.42M |
| Wages | $7.35M |
| Other Current Liabilities | $144.10M |
| Noncurrent Liabilities | $163.78M |
| Long-term Debt | $49.56M |
| Other Non-current Liabilities | $114.21M |
| Equity | $25.02M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $25.02M |
| Liabilities And Equity | $349.66M |
| Net Cash Flow From Operating Activities | $41.55M |
| Net Cash Flow From Operating Activities, Continuing | $41.55M |
| Net Cash Flow From Investing Activities | -$12.10M |
| Net Cash Flow From Investing Activities, Continuing | -$12.10M |
| Net Cash Flow From Financing Activities | -$11.20M |
| Net Cash Flow From Financing Activities, Continuing | -$11.20M |
| Net Cash Flow | $18.26M |
| Net Cash Flow, Continuing | $18.26M |
| Comprehensive Income/Loss | -$29.67M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$29.67M |
| Other Comprehensive Income/Loss | -$29.67M |